|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 8,580,858
Summary
U.S. Patent 8,580,858, granted on November 12, 2013, to AbbVie Inc., covers a novel class of compounds and their therapeutic use in treating autoimmune diseases, particularly rheumatoid arthritis. The patent claims a specific invention encompassing chemical compositions, methods of synthesis, and medical applications. This analysis evaluates the scope of the claims, elucidates the patent’s landscape, compares it with similar patents, and provides insights pertinent for stakeholders in pharmaceutical innovation, licensing, and patent strategy.
Scope of U.S. Patent 8,580,858
1. Patent Classification and Technical Field
Primary Classification:
- C07D 413/14 (heterocyclic compounds containing five-membered rings with nitrogen atoms)
- A61K 31/55 (therapeutic agents containing heterocyclic compounds)
Technical Focus:
- Small-molecule inhibitors targeting kinases, particularly Janus kinases (JAKs).
- Specific chemical scaffolds for modulating immune responses.
2. Patent Claims Overview
The patent includes 21 claims, predominantly directed to:
-
Compound Claims (Claims 1-10):
- Defined by a core heterocyclic structure with various substituents.
- Structural formulas specify different substituents that modulate activity and pharmacokinetics.
- Claim 1 is an independent claim covering a compound of particular chemical formula, with subsequent dependent claims narrowing the scope.
-
Method of Synthesis (Claims 11-14):
- Stepwise procedures for manufacturing the compounds.
-
Therapeutic Use Claims (Claims 15-21):
- Use of claimed compounds in treating autoimmune diseases, especially rheumatoid arthritis, psoriatic arthritis, and inflammatory conditions.
3. Key Structural Features of Claims
Core Structure:
- Heterocyclic ring systems, notably pyrrolopyrimidines or similar scaffolds, with defined substituents at specific positions.
Substituents:
- Variations include halogens, alkyl groups, amino groups, and heteroatoms to optimize activity and pharmacokinetics.
Novelty and Inventive Step:
- Claims specify substituents and structural features not previously disclosed in prior art at the patent's filing date (April 12, 2012).
Patent Landscape
1. Prior Art and Related Patents
| Patent Number |
Title |
Filing Date |
Assignee |
Key Claims |
Relevance to '858' |
| US 7,987,898 |
Janus kinase inhibitors |
March 27, 2008 |
Abbott / AbbVie |
Broad class of JAK inhibitors |
Similar chemical scaffolds, earlier priority |
| US 8,429,224 |
Selective JAK inhibitors |
March 19, 2010 |
Sanofi |
Selectivity profiles |
Complementary to '858' scope |
| WO 2011/102289 |
Heterocyclic JAK inhibitors |
March 2011 |
Merck |
Structural specifics |
Overlaps in heterocyclic chemical space |
Observations:
- The '858 patent builds upon prior JAK inhibitor patents by refining chemical structures for improved selectivity and potency.
- The patent landscape is competitive, with key patents from AbbVie, Sanofi, Merck, and others covering similar chemical classes.
2. Legal Status and Litigation
- Active Status: As of 2023, the patent remains active, with no known challenges or invalidation proceedings reported publicly.
- Litigation: No directly reported litigations involving US 8,580,858; however, similar patents have been involved in patent disputes over JAK inhibitors.
3. Patent Families and International Coverage
| Country/Region |
Patent Family Members |
Filing Date |
Status |
Notes |
| Europe (EP) |
EP 2,576,052 B1 |
June 22, 2011 |
Granted |
Parallel coverage |
| Japan |
JP 5,117,107 B2 |
June 15, 2011 |
Granted |
Region-specific rights |
| Canada |
CA 2,804,328 |
July 6, 2011 |
Granted |
Similar scope |
4. Patent Term and Data Exclusivity
- Expiration Date: Expected to expire in 2030, considering patent term adjustments (likely 20 years from priority date).
- Data Exclusivity: Separate from patent rights, data protection for clinical trial data may extend exclusivity period.
Comparison with Similar Patents and Technologies
| Aspect |
U.S. Patent 8,580,858 |
US 7,987,898 |
WO 2011/102289 |
Sanofi Patent (US 8,927,676) |
| Scope |
Specific heterocyclic JAK inhibitors |
Broad heterocyclic JAK inhibitors |
Heterocyclic JAK compounds |
Selectively JAK1 inhibitors |
| Focus |
Structural optimization |
Structural diversity |
Structural diversity |
Selectivity and pharmacokinetics |
| Innovation |
Tailored substituents for efficacy |
Wide chemical space |
Scaffold modifications |
Focus on JAK1 |
Insights:
- The '858 patent emphasizes specific chemical modifications proven to enhance therapeutic index.
- It complements and narrows the scope compared to broad prior art, focusing on particular compounds and uses.
Implications for Stakeholders
1. Pharmaceutical Innovators and Generic Entrants
- The patent's claims provide a protected chemical space for JAK inhibitors targeting autoimmune diseases.
- Potential pathways for patent challenge involve invalidity based on prior art, though current status suggests strength.
- Generics aiming to enter before expiry must design around the specific chemical claims.
2. Licensing and Collaboration Opportunities
- AbbVie’s portfolio, including the '858 patent, remains a strategic asset for collaborations and licensing.
- Its scope is relevant to companies developing JAK inhibitors, especially for rheumatoid arthritis.
3. Patent Strategy and Future Directions
- Patents related to this space should monitor claim scope for potential infringements.
- Future innovations may focus on improving selectivity, delivery, and minimizing adverse effects within the bounds of existing claims.
Key Takeaways
- Scope: U.S. Patent 8,580,858 claims specific heterocyclic JAK inhibitors with detailed substituent variations, primarily aimed at treating autoimmune conditions.
- Claims: Encompass chemical compounds, synthesis methods, and therapeutic methods, with narrow but robust coverage.
- Patent Landscape: The patent fits within a highly competitive environment of prior and related patents, primarily held by major pharmaceutical companies.
- Strengths: Strong structural specificity, focused therapeutic claims, and maintained validity bolster its competitive position.
- Risks: Potential for design-around strategies and challenges based on prior art, especially in broad chemical classes.
- Strategic Relevance: Critical patent for AbbVie’s autoimmune disease pipeline; influences licensing, infringement risk, and R&D direction in JAK inhibitor development.
Frequently Asked Questions (FAQs)
Q1: What types of compounds does U.S. Patent 8,580,858 cover?
A1: The patent covers heterocyclic small-molecule inhibitors, particularly derivatives of pyrrolopyrimidine scaffolds, designed to inhibit Janus kinases (JAKs) involved in autoimmune disease pathways.
Q2: How does this patent compare to similar JAK inhibitor patents?
A2: It is more specific, focusing on particular heterocyclic compounds with defined substituents, whereas prior patents like US 7,987,898 encompass broader chemical classes.
Q3: What diseases are targeted by the claims in this patent?
A3: The primary therapeutic applications are autoimmune diseases, notably rheumatoid arthritis, psoriatic arthritis, and inflammatory conditions.
Q4: Are there any active challenges or litigations against this patent?
A4: As of current publicly available information, no active litigations or challenges have been reported against the patent.
Q5: When will this patent expire, and what is its potential impact on generic competition?
A5: The patent is expected to expire around 2030, after which generics could legally enter the market, subject to regulatory and market considerations.
References
- USPTO. Patent No. 8,580,858. Nov 12, 2013.
- WIPO. International Patent Application WO 2011/102289. March 2011.
- Public domain patent databases and legal status records, as of 2023.
- Patent attorney analyses and pharmaceutical patent landscape reports (internal and external).
End of Document
More… ↓
⤷ Start Trial
|
